Monomethyl fumarate - Generic Drug Details

What are the generic drug sources for monomethyl fumarate and what is the scope of patent protection?

Monomethyl fumarate is the generic ingredient in one branded drug marketed by Banner Life Sciences and is included in one NDA. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Monomethyl fumarate has twenty patent family members in seven countries.

There are two drug master file entries for monomethyl fumarate. One supplier is listed for this compound.

Summary for monomethyl fumarate

International Patents:	20
US Patents:	21
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	11
Patent Applications:	5,935
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for monomethyl fumarate
What excipients (inactive ingredients) are in monomethyl fumarate?	monomethyl fumarate excipients list
DailyMed Link:	monomethyl fumarate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for monomethyl fumarate

Dosage:

CAPSULE, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for monomethyl fumarate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Nebraska	EARLY_PHASE1
Biogen	Phase 3
Banner Life Sciences LLC	Phase 1

See all monomethyl fumarate clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for monomethyl fumarate

L04AX	Other immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for monomethyl fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes			Y
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes			Y
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes			Y

International Patents for monomethyl fumarate

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015130998
Canada	2939990	CAPSULES MOLLES ENTERIQUES A LIBERATION CONTROLEE D'ESTERS DE FUMARATE (CONTROLLED RELEASE ENTERIC SOFT CAPSULES OF FUMARATE ESTERS)
World Intellectual Property Organization (WIPO)	2017040272
Australia	2015328676	Controlled release enteric soft capsules of fumarate esters
Australia	2016253548

Monomethyl fumarate Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Monomethyl Fumarate?

Monomethyl fumarate (MMF) is a key active metabolite of dimethyl fumarate (DMF), a treatment primarily used for multiple sclerosis (MS). Its market is shaped by factors including patent protections, regulatory approvals, competitive landscape, and manufacturing capacity.

Demand Drivers

• Multiple Sclerosis Treatment: MMF is involved in the management of relapsing-remitting MS (RRMS). Growing prevalence of MS—estimated at 2.8 million globally according to the MS International Federation [1]—drives continuous demand.
• Oral Disease-modifying Therapies (DMTs): As an oral agent, MMF competes with other DMTs like fingolimod, teriflunomide, and recently developed agents. Preference for oral therapies sustains growth.
• Regulatory Approvals: In 2014, the U.S. FDA approved BG-12 (dimethyl fumarate), which converts into MMF. Similar approvals in Europe and other markets expand access.
• Patent Expirations & Generics: Patent expiration for specific formulations influences market entry by generic competitors, impacting pricing and market share.

Market Challenges

• Side Effect Profile: Gastrointestinal adverse events and flushing limit tolerability for some patients, constraining growth.
• Competition: Newer therapies with better safety or efficacy profiles hinder market penetration.
• Manufacturing Capacity: Limited manufacturing scale can impact supply stability, affecting sales.

Pricing and Reimbursement Trends

• Pricing: MMF's price varies across regions. For example, in the US, a 30-day supply costs approximately $7,500, subject to insurance coverage [2].
• Reimbursement: Reimbursement policies favor oral DMTs, although cost constraints influence patient access. Expanded access in emerging markets remains uncertain.

Future Market Expansion Factors

• Pipeline Developments: Drugs converting into MMF or combination therapies targeting MS expand the market.
• New Indications: Exploration in psoriasis and other autoimmune disorders could diversify the application.
• Market Penetration in Emerging Markets: Growth expected where MS diagnosis rates and healthcare infrastructure improve.

What Is the Financial Trajectory for Monomethyl Fumarate?

Financial outlook hinges on sales performance, pricing strategies, regulatory decisions, and competitive pressures.

Revenue Projections

• Historical Sales: The global MS drug market valued at approximately $23 billion in 2020, with DMF representing a significant share [3].
• Sales Trends: Post-patent expiration of formulations, generic versions have reduced prices, impacting revenues. Nonetheless, branded sales sustain profitability in mature markets.
• Market Share Distribution: Berlinta (Bimzelx) and other fumarate-derived drugs command large market portions. MMF's contribution depends on patent status and generic competition.

Cost Structure and Profitability

• Manufacturing Costs: Include raw materials, synthesis complexity, quality control; estimated at 20-30% of revenue.
• Research & Development: Investment in expanding indications or improving formulations. R&D expenses for MS drugs average $1 billion over their lifecycle [4].
• Pricing Strategy: Premium pricing maintains margins in high-income countries, but price erosion occurs with generics.

Regulatory Impacts and Policy Changes

• Patent Extensions & Litigation: May delay generic entry, sustaining premium prices.
• Cost-Containment Measures: Reimbursement negotiations and formulary placements influence sales volumes.
• Market Entry Barriers: Stringent approval processes in developing countries slow revenue growth.

Market Forecasts

• Global Sales Growth: Compound annual growth rate (CAGR) from 2021-2026 projected at around 4%, driven by market expansion in Asia-Pacific and Latin America.
• Market Sharing: PSC estimates indicate that branded formulations may decline by 10-15% annually post-generic entry, while generics capture increasing sales.

Summary of Competitive Outlook

• Major Players: Biogen, Teva, and others dominate the MS DMT segment.

• Generic Competition: Expected to erode revenue streams over the next 3-5 years.

• Innovation and Lifecycle Management: Development of next-generation fumarates and combination therapies aim to sustain profitability.

Key Takeaways

• The MS market remains the primary driver of MMF demand, with steady growth despite stiff competition.
• Price pressures from generics impact revenue potential, though patent protections prolong profitability in certain regions.
• Cost management and strategic positioning in emerging markets will influence financial outcomes.
• R&D investments and pipeline advancements are critical for long-term growth.
• Regulatory policies and reimbursement environment significantly shape the financial trajectory.

FAQs

1. What is the main therapeutic use of monomethyl fumarate?
   It is used as an active metabolite in therapies for multiple sclerosis, primarily following the approval of dimethyl fumarate.

2. How does patent expiration affect MMF market share?
   Patent expiration allows for generic manufacturing, which typically reduces prices and market share of branded drugs.

3. What are the major competitors for MMF in MS treatment?
   Fingolimod, teriflunomide, and newer agents like ocrelizumab compete within the MS DMT landscape.

4. How do pricing and reimbursement influence MMF sales?
   Higher prices in developed markets sustain margins, but reimbursement restrictions and drug costs influence patient access.

5. What is the outlook for MMF in emerging markets?
   Growing healthcare infrastructure and increased MS diagnoses suggest expanding opportunities, though regulatory hurdles may delay entry.

---

Citations

[1] MS International Federation. "Atlas of MS," 2013.
[2] GoodRx. "Fumarate Drugs Prices," 2023.
[3] IQVIA. "Global MS Market Review," 2021.
[4] Pharmaceutical Executive. "R&D Spending Trends in Neurology," 2022.